Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7913 in advanced solid tumors
NCT04403308Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Jan 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magrolimab in solid tumor, sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse events up to 24 months. Started Jul 2020; status: completed.
02
Drugs
magrolimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04403308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04403308.